Form 4: UNITED THERAPEUTICS Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Paul A Mahon, EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp, sold 8,300 shares of common stock on August 6, 2026.

Summary

  • Option exercise/conversion: acquired 8,300 Common Stock at $146.03 ($1,212,049) on August 6, 2026; holds 53,472 after (Direct).
  • Open-market sale: disposed of 760 Common Stock at $512.92 ($389,817) on August 6, 2026; holds 52,712 after (Direct).
  • Open-market sale: disposed of 1,795 Common Stock at $514.82 ($924,106) on August 6, 2026; holds 50,917 after (Direct).
  • Open-market sale: disposed of 1,360 Common Stock at $515.93 ($701,665) on August 6, 2026; holds 49,557 after (Direct).
  • Open-market sale: disposed of 1,617 Common Stock at $516.93 ($835,869) on August 6, 2026; holds 47,940 after (Direct).
  • Open-market sale: disposed of 780 Common Stock at $517.94 ($403,994) on August 6, 2026; holds 47,160 after (Direct).
  • Open-market sale: disposed of 360 Common Stock at $518.82 ($186,776) on August 6, 2026; holds 46,800 after (Direct).
  • Open-market sale: disposed of 1,308 Common Stock at $521.50 ($682,118) on August 6, 2026; holds 45,492 after (Direct).
  • Open-market sale: disposed of 320 Common Stock at $522.39 ($167,166) on August 6, 2026; holds 45,172 after (Direct).
  • Option exercise/conversion: disposed of 8,300 Stock Option on August 6, 2026; holds 72,440 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,291,512 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Paul A Mahon — Officer (EVP & GENERAL COUNSEL)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-06Option exercise/conversionCommon Stock8,300$146$1.2M53,472
2026-08-06Open-market saleCommon Stock760$513$389.8K52,712
2026-08-06Open-market saleCommon Stock1,795$515$924.1K50,917
2026-08-06Open-market saleCommon Stock1,360$516$701.7K49,557
2026-08-06Open-market saleCommon Stock1,617$517$835.9K47,940
2026-08-06Open-market saleCommon Stock780$518$404.0K47,160
2026-08-06Open-market saleCommon Stock360$519$186.8K46,800
2026-08-06Open-market saleCommon Stock1,308$521$682.1K45,492
2026-08-06Open-market saleCommon Stock320$522$167.2K45,172
2026-08-06Option exercise/conversionStock Option8,300——72,440

Key Dates

DateDescription
2026-08-06Option exercise/conversion (8,300 shares)
2026-08-06Open-market sale (760 shares)
2026-08-06Open-market sale (1,795 shares)
2026-08-06Open-market sale (1,360 shares)
2026-08-06Open-market sale (1,617 shares)
2026-08-06Open-market sale (780 shares)
2026-08-06Open-market sale (360 shares)
2026-08-06Open-market sale (1,308 shares)
2026-08-06Open-market sale (320 shares)
2026-08-06Option exercise/conversion (8,300 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Paul A Mahon

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.